idronoxil

Idronoxil is a synthetic flavonoid derivative structurally related to genistein, developed primarily for cancer treatment. It has been studied as an **anticancer agent** due to its ability to regulate multiple signal transduction pathways, induce apoptosis, arrest the cell cycle, inhibit angiogenesis, and modulate the immune system[1][4][7]. Idronoxil acts by disrupting the expression of FLICE-inhibitory protein (FLIP) and promoting caspase-dependent and -independent degradation of the X-linked inhibitor of apoptosis (XIAP)[4][7]. It also inhibits plasma membrane electron transport and sphingosine kinase activity, sensitizing tumor cells to chemotherapy and radiotherapy and thereby overcoming drug resistance[4][1]. While idronoxil displayed low bioavailability with oral or intravenous administration, rectal suppository formulations (such as NOX66) are in clinical development to improve systemic exposure[3][6][9]. It is known under the trade names NOX66 and Veyonda and has orphan drug designation for soft tissue sarcoma[6]. Development work has focused on its ability to enhance the efficacy of cytotoxic agents—including carboplatin, paclitaxel, and ^177Lu-PSMA-617—in patients with advanced solid tumors and metastatic castration-resistant prostate cancer[9][3].

Brand names

NOX66NOX-66NOX 66Veyonda

Other names

idronoxilphenoxodioldehydroequolhaginin E